EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

CHICAGO 2025

Breast Cancer

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

CHICAGO 2025

Breast Cancer

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

ESMO 2025

Breast Cancer

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

ESMO 2025

Breast Cancer

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

ESMO 2025

Breast Cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

Breast Cancer

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

Eur J Cancer

Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S

doi: 10.1016/j.ejca.2025.115225

Breast Cancer

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Ann Oncol

Mayer EL, Bidard FC, Park YH, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching PA, Nowecki Z, Chen SC, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn JH, Zhu Y, Leddin I, Miralles MS, Bartlett CH, Turner N

doi: 10.1016/j.annonc.2025.10.006

Related content

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Advancing Breast Cancer Treatment with Elacestrant

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy